Steroid-Sparing Agents
Cyclophosphamide achieves a sustained remission rate of 42% at 2 years but is limited by significant side effects. No consensus exists for optimal management of frequently relapsing or steroid-dependent nephrotic syndrome. IPNA guidelines…
1 sources - 4 claims
Cyclophosphamide achieves a sustained remission rate of 42% at 2 years but is limited by significant side effects. No consensus exists for optimal management of frequently relapsing or steroid-dependent nephrotic syndrome. IPNA guidelines list potential oral steroid-sparing agents without specifying a preference among them. Relapse occurs in 75% of patients after cyclosporine withdrawal and in over 90% after mycophenolate mofetil withdrawal.